Brief: Evaxion Presents A New Source Of Ai-Derived Immunotherapeutic Targets Strongly Associated With The Overall Survival Of Cancer Patients
23/03/2023 13:16
March 23 (Reuters) - Evaxion Biotech A/S EVAX.O :
* EVAXION PRESENTS A NEW SOURCE OF AI-DERIVED
IMMUNOTHERAPEUTIC
TARGETS STRONGLY ASSOCIATED WITH THE OVERALL SURVIVAL OF CANCER
PATIENTS
Source text for Eikon: ID:nGNX6sj20F
Further company coverage: EVAX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma